Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aduro Biotech, Inc.
With
Hanlee P. Ji, MD
This single arm study is designed to evaluate the safety and tolerability of a personalized treatment in adults with metastatic colorectal cancer by first analyzing the expression of tumor-associated antigens and then treating the patients with a personalized live, attenuated, double-deleted Listeria monocytogenes (pLADD)-based immunotherapy. pLADD is based on the attenuated form of Listeria monocytogenes that has been genetically modified to reduce its ability to cause disease, while maintaining its ability to stimulate a potent immune response. pLADD is manufactured using patient-specific antigens and is therefore individualized to each patient.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
metastatic colorectal cancer (mCRC) that is microsatellite stable (MSS)
able to provide adequate tumor tissue from at least 1 accessible tumor site
completed or have developed intolerance to a course of oxaliplatin- or irinotecan-based frontline therapy at Screening
on maintenance standard-of-care chemotherapies or on treatment holiday
Eastern Cooperative Oncology Group (ECOG) 0 or 1
adequate organ function
progression of disease at the time of Enrollment
You may not be if
BRAF V600E mutation
known allergy to both penicillin and sulfa drugs
implanted devices that cannot be easily removed
immunodeficiency, immune compromised state or receiving immunosuppressive therapy